Enhertu pushes on the HER2-low door once again
Daiichi and AstraZeneca claim another breast cancer success, and further evidence of the ADC’s activity in very low HER2 expression.
ASCO 2024 preview – Astra’s plenary double
Abstract titles reveal some of ASCO’s key datasets.
Roche trims its pipeline again
Belvarafenib heads back to Hanmi and LY6G6D targeting takes a blow.
Third time lucky for Roche in MAGE-A4?
The Swiss company is still interested in this antigen, after discontinuing two earlier clinical projects.
CCR8 expectations
Blockade of CCR8 has quietly emerged as a hot oncology target, especially for anti-PD-(L)1 MAb combinations.
GSK’s $625m TIGIT bet approaches crunch time
Readout of the delayed Galaxies Lung-201 study is due imminently.
